Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Emerg Infect Dis ; 18(4)2012 Apr.
Article in English | MEDLINE | ID: mdl-22469519

ABSTRACT

To prioritize 100 animal diseases and zoonoses in Europe, we used a multicriteria decision-making procedure based on opinions of experts and evidence-based data. Forty international experts performed intracategory and intercategory weighting of 57 prioritization criteria. Two methods (deterministic with mean of each weight and probabilistic with distribution functions of weights by using Monte Carlo simulation) were used to calculate a score for each disease. Consecutive ranking was established. Few differences were observed between each method. Compared with previous prioritization methods, our procedure is evidence based, includes a range of fields and criteria while considering uncertainty, and will be useful for analyzing diseases that affect public health.


Subject(s)
Foodborne Diseases/classification , Health Priorities , Zoonoses/classification , Agriculture , Animals , Decision Support Techniques , Europe , Evidence-Based Medicine , Food Safety , Humans , Models, Statistical , Monte Carlo Method , Public Health , Regression Analysis , Risk Assessment , Zoonoses/transmission
2.
Bull Acad Natl Med ; 196(3): 589-90, 619-20, 2012 Mar.
Article in French | MEDLINE | ID: mdl-23472348

ABSTRACT

According to the IFAH, veterinary vaccines currently account for 26% of the global market in veterinary medicines, reflecting the importance of vaccines in animal health, as well as the number of wild and domesticated target species, and the monospecific nature of most vaccines. Multispecies vaccines include tetanus and rabies. In 2010, the number of food-producing animals was estimated to be roughly 20 billion and is rising gradually. Fowl currently represent the main food species. Veterinary vaccination has allowed the eradication of rinderpest, as officially declared last year (2011), jointly by the World Organisation for Animal Health (OIE) and the Food and Agriculture Organisation of the United Nations (FAO). Rinderpest was a real scourge, and was only the second viral disease to be totally eradicated (after human smallpox). One characteristic of veterinary vaccination is the DIVA approach, "differentiating infected from vaccinated animals". The DIVA strategy is especially interesting for regulated control of diseases like foot-and-mouth disease, infectious bovine rhinotracheitis, pseudorabies, and classical swine fever. DIVA vaccination requires prior serological testing. Vaccination is also used for wild animals such as foxes (rabies) and wild boars (classical swine fever). "In ovo" vaccination of fowl on day 18 of the incubation period is used to prevent Marek's disease for instance, and double vaccination (vector and insert) to prevent both Marek's disease and Gumboro's disease in fowl. Animal vaccination can also help to protect human health, as illustrated by fowl vaccination against salmonellosis.


Subject(s)
Vaccination/veterinary , Vaccines , Animals
3.
Vet Res ; 42: 70, 2011 Jun 02.
Article in English | MEDLINE | ID: mdl-21635726

ABSTRACT

The domestic animals/wildlife interface is becoming a global issue of growing interest. However, despite studies on wildlife diseases being in expansion, the epidemiological role of wild animals in the transmission of infectious diseases remains unclear most of the time. Multiple diseases affecting livestock have already been identified in wildlife, especially in wild ungulates. The first objective of this paper was to establish a list of infections already reported in European wild ungulates. For each disease/infection, three additional materials develop examples already published, specifying the epidemiological role of the species as assigned by the authors. Furthermore, risk factors associated with interactions between wild and domestic animals and regarding emerging infectious diseases are summarized. Finally, the wildlife surveillance measures implemented in different European countries are presented. New research areas are proposed in order to provide efficient tools to prevent the transmission of diseases between wild ungulates and livestock.


Subject(s)
Animals, Wild , Artiodactyla , Communicable Diseases/veterinary , Epidemiological Monitoring/veterinary , Livestock , Animals , Communicable Disease Control/legislation & jurisprudence , Communicable Disease Control/methods , Communicable Diseases/classification , Communicable Diseases/epidemiology , Communicable Diseases/etiology , Communicable Diseases, Emerging/classification , Communicable Diseases, Emerging/epidemiology , Communicable Diseases, Emerging/etiology , Communicable Diseases, Emerging/veterinary , Europe/epidemiology , Risk Factors
4.
Biologicals ; 38(3): 332-4, 2010 May.
Article in English | MEDLINE | ID: mdl-20456974

ABSTRACT

Vaccination is one of the most important public health accomplishments. However, since vaccine preparation involves the use of materials of biological origin, vaccines are subject to contamination by micro-organisms. In fact, vaccine contamination has occurred; a historical example of vaccine contamination, for example, can be found in the early days of development of the smallpox vaccine. The introduction of new techniques of vaccine virus production on cell cultures has lead to safer vaccines, but has not completely removed the risk of virus contamination. There are several examples of vaccine contamination, for example, contamination of human vaccines against poliomyelitis by SV40 virus from the use of monkey primary renal cells. Several veterinary vaccines have been contaminated by pestiviruses from foetal calf serum. These incidents have lead industry to change certain practices and regulatory authorities to develop more stringent and detailed requirements. But the increasing number of target species for vaccines, the diversity of the origin of biological materials and the extremely high number of known and unknown viruses and their constant evolution represent a challenge to vaccine producers and regulatory authorities.


Subject(s)
Drug Contamination/prevention & control , Veterinary Drugs/standards , Viral Vaccines/standards , Animals , Humans , Risk Assessment , Risk Factors , Vaccination/veterinary , Veterinary Drugs/administration & dosage , Viral Vaccines/administration & dosage , Viral Vaccines/immunology , Viruses/immunology
7.
Vet Res ; 38(6): 819-34, 2007.
Article in English | MEDLINE | ID: mdl-17727807

ABSTRACT

We report DNA immunisation experiments in cattle using plasmid constructs that encoded glycoprotein E2 from bovine viral diarrhoea virus (BVDV)-1 (E2.1) and BVDV-2 (E2.2). The coding sequences were optimised for efficient expression in mammalian cells. A modified leader peptide sequence from protein gD of BoHV1 was inserted upstream of the E2 coding sequences for efficient membrane export of the proteins. Recombinant E2 were efficiently expressed in COS7 cells and they presented the native viral epitopes as judged by differential recognition by antisera from cattle infected with BVDV-1 or BVDV-2. Inoculation of pooled plasmid DNA in young cattle elicited antibodies capable of neutralising viral strains representing the major circulating BVDV genotypes.


Subject(s)
Bovine Virus Diarrhea-Mucosal Disease/immunology , Bovine Virus Diarrhea-Mucosal Disease/prevention & control , Diarrhea Viruses, Bovine Viral/immunology , Vaccines, DNA/immunology , Viral Envelope Proteins/chemistry , Viral Envelope Proteins/immunology , Viral Vaccines/immunology , Administration, Intranasal , Animals , Antibodies, Viral/blood , Base Sequence , Cattle , Cloning, Molecular , Injections, Intradermal , Injections, Intramuscular , Male , Vaccines, DNA/administration & dosage , Vaccines, DNA/genetics , Viral Envelope Proteins/genetics , Viral Vaccines/administration & dosage , Viral Vaccines/chemistry , Viral Vaccines/genetics
8.
Vaccine ; 25(41): 7007-11, 2007 Oct 10.
Article in English | MEDLINE | ID: mdl-17728022

ABSTRACT

As the 21st century unfolds, infectious diseases remain one of the most significant threats to our economy, our food animal production systems, animal welfare, and most importantly, the lives of people worldwide, regardless of their economic standing. The potential use of biological threat agents for terrorism or biowarfare further undermines the security of our society. Arguably, vaccines represent the single most cost-effective, medically delivered strategy for confronting these challenges. The workshop "Advances in Immunology and Vaccine Discovery" was organized to address these challenges, based on the conviction that the interface between immunology and vaccinology offers the best prospects for major breakthroughs in vaccine discovery and development. Six focus areas were identified by workshop organizers: (1) pathogen immune evasion; (2) innate immunity; (3) mucosal immunity; (4) immunogenetics; (5) comparative immunology; and (6) genomics. These areas provided opportunities to elucidate how protective immunity may relate to the disruption of the molecular mechanisms that underlie host-pathogen interactions. A report generated by workshop organizers and participants provides key recommendations and identifies important research gaps, needs, future steps, and potential strategic US-EU collaborations. The report is available on line through ScienceDirect (URL).


Subject(s)
Communicable Disease Control/methods , Communicable Diseases/immunology , Vaccines/immunology , Humans
9.
Clin Microbiol Rev ; 20(3): 489-510, table of contents, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17630337

ABSTRACT

The major goals of veterinary vaccines are to improve the health and welfare of companion animals, increase production of livestock in a cost-effective manner, and prevent animal-to-human transmission from both domestic animals and wildlife. These diverse aims have led to different approaches to the development of veterinary vaccines from crude but effective whole-pathogen preparations to molecularly defined subunit vaccines, genetically engineered organisms or chimeras, vectored antigen formulations, and naked DNA injections. The final successful outcome of vaccine research and development is the generation of a product that will be available in the marketplace or that will be used in the field to achieve desired outcomes. As detailed in this review, successful veterinary vaccines have been produced against viral, bacterial, protozoal, and multicellular pathogens, which in many ways have led the field in the application and adaptation of novel technologies. These veterinary vaccines have had, and continue to have, a major impact not only on animal health and production but also on human health through increasing safe food supplies and preventing animal-to-human transmission of infectious diseases. The continued interaction between animals and human researchers and health professionals will be of major importance for adapting new technologies, providing animal models of disease, and confronting new and emerging infectious diseases.


Subject(s)
Animal Diseases/prevention & control , Vaccination/veterinary , Vaccines , Allergens/therapeutic use , Animals , Animals, Domestic , Bacterial Vaccines , Cancer Vaccines , Communicable Disease Control , Fertility , Hypersensitivity/prevention & control , Neoplasms/prevention & control , Protozoan Vaccines , Reproduction , Vaccines, Subunit , Vaccines, Synthetic , Viral Vaccines
10.
Virus Res ; 115(2): 112-21, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16140410

ABSTRACT

Caprine herpesvirus 1 (CpHV-1) is responsible of systemic infection in neonatal kids as well as abortion and fertility disorders in adult goats. This virus is closely related to bovine herpesvirus 1 (BoHV-1) which causes infectious bovine rhinotracheitis. Glycoprotein D (gD) mediates important functions in alphaherpesviruses and is also a main immunogen. The sequence of CpHV-1 gD gene and the biochemical properties of its translation product were analyzed and compared to those of BoHV-1 and other alphaherpesviruses. A relatively high homology was found between CpHV-1 and BoHV-1 glycoproteins D amino acid sequences (similarity of 68.8%). Moreover, six cysteine residues are conserved by CpHV-1 gD and the other studied alphaherpesviruses. CpHV-1 gD has a molecular mass similar to BoHV-1 gD and contains complex N-linked oligosaccharides. In contrast to the BoHV-1 gD, CpHV-1 gD is expressed as a late protein. In spite of the observed differences which could influence its biological functions, CpHV-1 gD shares most characteristics with other alphaherpesviruses and especially BoHV-1.


Subject(s)
Glycoproteins/genetics , Varicellovirus/chemistry , Varicellovirus/genetics , Viral Envelope Proteins/chemistry , Viral Envelope Proteins/genetics , Alphaherpesvirinae/chemistry , Alphaherpesvirinae/genetics , Amino Acid Sequence , Animals , Cattle , Cell Line , Conserved Sequence , Cysteine/genetics , DNA, Viral/chemistry , DNA, Viral/genetics , Gene Expression Regulation, Viral , Glycoproteins/chemistry , Molecular Sequence Data , Molecular Weight , Oligosaccharides/analysis , Oligosaccharides/chemistry , Sequence Analysis, DNA , Sequence Homology, Amino Acid
11.
Environ Manage ; 35(3): 292-302, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15925973

ABSTRACT

Oral vaccination of foxes (OVF) is a powerful tool to combat rabies in wildlife, and large parts of western Europe have been freed from rabies using this tool. Nevertheless, the success of OVF, given with the number of campaigns needed to eliminate the disease, depends on many factors. This article for the first time focuses on and assesses difference in OVF with respect to the spatial setting of vaccinated areas with time. The size of the areas vaccinated with time and the size of the overlapping area of consecutively vaccinated areas are particularly considered. In order to integrate these two aspects into one single figure, an Area Index is proposed ranging between 0 and 1. A statistical analysis indicates that the number of campaigns needed for rabies elimination significantly decreases on condition that the total rabies endemic area is consecutively treated right from the beginning of oral vaccination. Hence, from an economical and environmental point of view, vaccination areas should be selected the way that guarantees an Area Index close to 1. The concept of an Area Index, as described here, is a useful tool not only in the context of OVF, but it could also be used for other control schemes against infectious diseases in wildlife.


Subject(s)
Foxes/microbiology , Rabies Vaccines/administration & dosage , Rabies/epidemiology , Rabies/prevention & control , Administration, Oral , Animals , Animals, Wild , Environmental Monitoring , Epidemiological Monitoring , Europe/epidemiology , Population Density , Rabies/veterinary , Retrospective Studies
12.
J Clin Microbiol ; 42(3): 1228-35, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15004081

ABSTRACT

The control of infectious bovine rhinotracheitis induced by bovine herpesvirus 1 (BoHV-1) requires sensitive and specific diagnostic assays. As BoHV-1 is antigenically and genetically related to four other alphaherpesviruses of ruminants-namely, BoHV-5, caprine herpesvirus 1 (CpHV-1), cervine herpesvirus 1 (CvHV-1) and CvHV-2-diagnostic tests able to discriminate BoHV-1 from these related viruses are needed to avoid misdiagnosis, especially because some of these viruses are able to cross the species barrier. In this study, murine monoclonal antibodies (MAbs) specific for BoHV-1, BoHV-5, CpHV-1, CvHV-1, and CvHV-2 were produced with the aim of setting up an immunofluorescence assay able to discriminate between these related herpesviruses. Produced MAbs were selected for their viral specificity by enzyme-linked immunosorbent assay and indirect immunofluorescence staining of virus-infected cells. Radioimmunoprecipitation characterization of the selected MAbs revealed that four of them are directed against glycoprotein C (gC) and one of them is directed against gD of these related viruses. The obtained results demonstrate that the antibodies produced allow an unambiguous discrimination of each of the four alphaherpesviruses related to BoHV-1.


Subject(s)
Alphaherpesvirinae/isolation & purification , Antigens, Viral/analysis , Herpesvirus 1, Bovine/isolation & purification , Alphaherpesvirinae/immunology , Animals , Antibodies, Monoclonal , Cattle , Cattle Diseases/diagnosis , Cattle Diseases/virology , Cell Line , Deer , Diagnosis, Differential , Enzyme-Linked Immunosorbent Assay , Goat Diseases/diagnosis , Goat Diseases/virology , Goats , Herpesviridae Infections/diagnosis , Herpesviridae Infections/veterinary , Herpesvirus 1, Bovine/immunology , Kidney , Mice , Mice, Inbred BALB C
13.
J Gen Virol ; 85(Pt 2): 355-367, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14769893

ABSTRACT

The Bo17 gene of bovine herpesvirus 4 (BoHV-4) is the only virus gene known to date that encodes a homologue of the cellular core 2 beta-1,6-N-acetylglucosaminyltransferase-mucine type (C2GnT-M). Recently, our phylogenetic study revealed that the Bo17 gene has been acquired from an ancestor of the African buffalo around 1.5 million years ago. Despite this recent origin, the Bo17 sequence has spread to fixation in the virus population possibly by natural selection. Supporting the latter hypothesis, it has been shown by our group for the V. test strain that Bo17 is expressed during BoHV-4 replication in vitro, and that Bo17 expression product (pBo17) has all three enzymic activities exhibited by cellular C2GnT-M, i.e. core 2, core 4 and I branching activities. In the present study, firstly it was investigated whether encoding a functional C2GnT-M is a general property of BoHV-4 strains. Analysis of nine representative strains of the BoHV-4 species revealed that all of them express the Bo17 gene and the associated core 2 branching activity during virus replication in vitro. Secondly, in order to investigate the roles of Bo17, its kinetic class of expression was analysed and a deleted recombinant strain was produced. These experiments revealed that Bo17 is expressed as an early gene which is not essential for virus replication in vitro. However, comparison of the structural proteins, produced by the wild-type, the revertant and the deleted viruses, by 2D gels demonstrated that pBo17 contributes to the post-translational modifications of structural proteins. Possible roles of Bo17 in vivo are discussed.


Subject(s)
Herpesvirus 4, Bovine/metabolism , N-Acetylglucosaminyltransferases/metabolism , Protein Processing, Post-Translational , Viral Structural Proteins/metabolism , Enzyme Induction , Gene Deletion , Gene Expression , Herpesvirus 4, Bovine/genetics , N-Acetylglucosaminyltransferases/biosynthesis , N-Acetylglucosaminyltransferases/genetics , Species Specificity , Virus Replication
14.
J Wildl Dis ; 38(3): 539-44, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12243138

ABSTRACT

Adult vampire bats (Desmodus rotundus) were vaccinated by intramuscular, scarification, oral, or aerosol routes (n = 8 in each group) using a vaccinia-rabies glycoprotein recombinant virus. Sera were obtained before and 30 days after vaccination. All animals were then challenged intramuscularly with a lethal dose of rabies virus. Neutralizing antirabies antibodies were measured by rapid fluorescent focus inhibition test (RFFIT). Seroconversion was observed with each of the routes employed, but some aerosol and orally vaccinated animals failed to seroconvert. The highest antibody titers were observed in animals vaccinated by intramuscular and scarification routes. All animals vaccinated by intramuscular, scarification, and oral routes survived the viral challenge, but one of eight vampire bats receiving aerosol vaccination succumbed to the challenge. Of 31 surviving vaccinated and challenged animals, nine lacked detectable antirabies antibodies by RFFIT (five orally and four aerosol immunized animals). In contrast, nine of 10 non-vaccinated control bats succumbed to viral challenge. The surviving control bat had antiviral antibodies 90 days after viral challenge. These results suggest that the recombinant vaccine is an adequate and safe immunogen for bats by all routes tested.


Subject(s)
Chiroptera , Rabies Vaccines , Rabies/veterinary , Vaccination/veterinary , Administration, Cutaneous , Administration, Oral , Aerosols , Animals , Antibodies, Viral/blood , Injections, Intramuscular/veterinary , Rabies/prevention & control , Rabies Vaccines/administration & dosage , Rabies virus/immunology , Vaccination/methods , Vaccination/standards , Vaccines, Synthetic/administration & dosage
15.
J Allergy Clin Immunol ; 110(3): 443-9, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12209092

ABSTRACT

BACKGROUND: CD40 engagement enhances eosinophil survival, suggesting a role for this receptor in the development of eosinophilia. OBJECTIVE: We examined whether CD40 enhances eosinophil survival by inducing the expression of antiapoptotic proteins. Three members of the inhibitor of apoptosis protein (IAP) family, namely cellular (c)-IAP1, c-IAP2, and XIAP, and 2 antiapoptotic proteins of the Bcl-2 family, namely Bcl-x(L) and Bfl-1/A1, were investigated. METHODS: Blood and sputum were obtained from healthy subjects and atopic asthmatic patients. Blood eosinophils were isolated by means of magnetic selection. Expression of CD40, IAPs, and Bcl-2 proteins was investigated by using flow cytometry, immunoblotting, or both. CD40 stimulation was achieved with agonistic antibodies or soluble ligands. Apoptosis was assessed by staining with propidium iodide and FITC-conjugated annexin-V. c-IAP2 expression was inhibited with antisense oligonucleotides. RESULTS: Freshly isolated eosinophils from healthy and asthmatic patients did not express CD40. Conversely, eosinophils expressed CD40 spontaneously when cultured for 48 hours. At this time point, CD40 stimulation significantly delayed eosinophil apoptosis. Inhibition of eosinophil apoptosis was accompanied by induction of c-IAP2 but not c-IAP1, XIAP, Bcl-x(L), or Bfl-1/A1 expression. Antisense knockdown of c-iap2 abolished CD40-induced enhancement of eosinophil survival. Sputum cells from asthmatic patients, unlike those from healthy subjects, substantially expressed CD40 and c-IAP2. Moreover, a strong correlation was found between the percentage of eosinophils in the sputum from asthmatic patients and the sputum level of CD40 and c-IAP2 expression. CONCLUSION: The results demonstrate that CD40 engagement enhances eosinophil survival through induction of c-IAP2 expression and suggest a role for this mechanism in allergic inflammation.


Subject(s)
CD40 Antigens/physiology , Eosinophils/immunology , Hypersensitivity, Immediate/immunology , Protein Biosynthesis , Proteins , Adult , Apoptosis , Asthma/immunology , CD40 Antigens/metabolism , Cell Survival , Cells, Cultured , Eosinophilia/immunology , Eosinophils/cytology , Humans , Hypersensitivity, Immediate/pathology , Inflammation/immunology , Inhibitor of Apoptosis Proteins , Sputum/cytology , Ubiquitin-Protein Ligases
16.
Emerg Infect Dis ; 8(9): 930-6, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12194769

ABSTRACT

Populations of bank voles (Clethrionomys glareolus) were monitored during a 4-year study in southern Belgium to assess the influence of agonistic behavior, reproductive status, mobility, and distribution of the rodents on the dynamics of Puumala virus (abbreviation: PUUV; genus: Hantavirus) infection. Concordance was high between data from serologic testing and results of viral RNA detection. Wounds resulting from biting or scratching were observed mainly in adult rodents. Hantavirus infection in adults was associated with wounds in the fall, i.e., at the end of the breeding season, but not in spring. In addition, sexually active animals were significantly more often wounded and positive for infection. Hantavirus infection was associated with higher mobility in juvenile and subadult males. Seroconversions observed 6 months apart also occurred more frequently in animals that had moved longer distances from their original capture point. During nonepidemic years, the distribution of infection was patchy, and positive foci were mainly located in dense ground vegetation.


Subject(s)
Arvicolinae/physiology , Arvicolinae/virology , Behavior, Animal/physiology , Hantavirus Infections/epidemiology , Puumala virus/isolation & purification , Rodent Diseases/epidemiology , Age Factors , Animals , Belgium/epidemiology , Disease Susceptibility , Environment , Female , Hantavirus Infections/transmission , Hantavirus Infections/virology , Locomotion , Male , Population Dynamics , Prevalence , Reproduction , Rodent Diseases/transmission , Rodent Diseases/virology , Seasons , Sex Factors , Wounds and Injuries/virology
17.
Blood ; 99(10): 3683-91, 2002 May 15.
Article in English | MEDLINE | ID: mdl-11986224

ABSTRACT

Constitutive nuclear factor kappaB (NF-kappaB) activity protects quiescent mature immune cells from spontaneous apoptosis. Here, we examined whether NF-kappaB exerts its antiapoptotic function in these cells through the control of Bcl-2 family proteins. Specific pharmacologic inhibitors of NF-kappaB were used to achieve total NF-kappaB inactivation in quiescent human blood lymphocytes, granulocytes, and monocytes. NF-kappaB inhibition induced drastic lymphocyte and granulocyte apoptosis, but only moderate monocyte apoptosis. T- and B-cell apoptosis was slow and associated with a gradual down-regulation of the prosurvival Bcl-2 family proteins Bcl-x(L) and Bcl-2, respectively. By contrast, granulocyte apoptosis was fast and accompanied by a rapid cellular accumulation of Bcl-x(S), the proapoptotic Bcl-x isoform that is generated from alternative splicing of the bcl-x pre-mRNA. Finally, antisense bcl-x(L) and bcl-2 knockdown in T and B cells, respectively, and induction of Bcl-x(S) expression in granulocytes through antisense oligonucleotide-mediated redirection of bcl-x pre-mRNA splicing were sufficient to induce significant apoptosis in these cells. Taken together, these results reveal that basal NF-kappaB activity preserves homeostasis of quiescent mature lymphocytes and granulocytes through regulation of distinct members of the Bcl-2 family. This study sheds light on the constitutive mechanisms by which NF-kappaB maintains defense integrity.


Subject(s)
Apoptosis , Granulocytes/metabolism , Lymphocytes/metabolism , NF-kappa B/metabolism , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Cell Differentiation , Cells, Cultured , Down-Regulation , Gene Expression Regulation , Granulocytes/cytology , Homeostasis , Humans , Kinetics , Lymphocytes/cytology , NF-kappa B/antagonists & inhibitors , NF-kappa B/physiology , Oligonucleotides, Antisense/pharmacology , Proto-Oncogene Proteins c-bcl-2/genetics , RNA, Messenger/biosynthesis , Transcription, Genetic , bcl-X Protein
18.
J Immunol ; 168(10): 5318-25, 2002 May 15.
Article in English | MEDLINE | ID: mdl-11994490

ABSTRACT

An anti-inflammatory role and therapeutic potential for cyclopentenone PGs (cyPGs) has been suggested, based on observations that levels of cyPGs in exudates increase during the resolution phase of inflammation, and that exogenous cyPGs may attenuate the inflammatory response in vivo and in vitro mainly through inhibition of NF-kappaB, a critical activator of inflammatory gene expression. However, exogenous cyPGs inhibit NF-kappaB only at concentrations substantially higher than those of endogenous cyPGs present in inflammatory fluids, thus challenging the hypothesis that cyPGs are naturally occurring inhibitors of inflammation and suggesting that cyPGs at low concentrations might have previously unappreciated effects. In this study, using various cell types, we report that cyPGs, when used at concentrations substantially lower than required for NF-kappaB inhibition (viz, low micromolar concentrations), significantly potentiate the inflammatory response to TNF-alpha. At these concentrations, cyPGs induce production of reactive oxygen species, thereby synergizing with TNF-alpha to activate the extracellular signal-regulated kinase 1/2, an activation which in turn potentiates proinflammatory cytokine expression at both transcriptional and posttranscriptional levels. Our study establishes a proinflammatory role for cyPGs at low micromolar concentrations, raises the possibility that cyPGs do not act as physiologic anti-inflammatory mediators, and questions the therapeutic potential of these compounds.


Subject(s)
Cyclopentanes/pharmacology , Inflammation Mediators/physiology , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinases/metabolism , NF-kappa B/antagonists & inhibitors , Oxidative Stress/immunology , Prostaglandin D2/analogs & derivatives , Prostaglandins/physiology , Adjuvants, Immunologic/metabolism , Adjuvants, Immunologic/physiology , Cells, Cultured , Cyclopentanes/metabolism , Cytokines/biosynthesis , Dose-Response Relationship, Immunologic , Enzyme Activation/immunology , HeLa Cells/immunology , HeLa Cells/metabolism , HeLa Cells/pathology , Humans , Inflammation Mediators/metabolism , Mitogen-Activated Protein Kinase 1/physiology , Mitogen-Activated Protein Kinase 3 , Mitogen-Activated Protein Kinases/physiology , NF-kappa B/metabolism , Prostaglandin D2/metabolism , Prostaglandin D2/physiology , Prostaglandins/metabolism , Prostaglandins A/metabolism , Prostaglandins A/pharmacology , Protein Processing, Post-Translational/immunology , Reactive Oxygen Species/immunology , Reactive Oxygen Species/metabolism , Transcription, Genetic/immunology , Tumor Cells, Cultured/enzymology , Tumor Cells, Cultured/immunology , Tumor Necrosis Factor-alpha/pharmacology , U937 Cells/immunology , U937 Cells/metabolism , U937 Cells/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...